In addition, ACC inhibitors (ACCi) in NASH patients has been reported to increase apoB-containing lipoproteins as well as VLDL particle number, triglyceride (TG) content, and secretion (8, 10, 11, 12, 13, 14, 15, 16). This evidence concerns the gene APOB and metabolic dysfunction-associated steatohepatitis.